Article of interest_Rethinking drug discovery
Subhadra Dravida, Founder and CEO of Tran-Scell Biologics& TranSTox BioApplications India and Prabhat Arya, Department of Organic and Medicinal Chemistry Dr. Reddy's Institute of Life Sciences (DRILS) University of Hyderabad Campus India write about the rethinking drug discovery. For full article, please visit:
Drug discovery is a tough business! At the same time, it is the domain that provides an opportunity to improve the quality of human health and allows recovering from the suffering due to various biological disorders. In the past decades, we have witnessed a major limitation in creating the next-generation drugs despite a significant boost in the financial spending for research and development.
Summary
As we have seen for the past several years, the current practice of drug discovery seems to be a losing battle and not much has come out to benefit the society that is desperately looking for next generation effective medicines at an affordable cost. We are hoping that through embracing some of these new research working models and building like-minded teams that are a nice blend of skill-sets from academia and pharma sector would allow reaching the objectives that are not possible to be achieved with classical working models. A challenging task is to build teams to undertake high-risk research programmes, and, this requires a deeper understanding of the need of so called ‘collective competence’. Only time will tell, whether, climbing this mountain would lead to a productive path that the patient community would benefit from, and this remains to be seen in days ahead!
Comments
Post a Comment